Innate Pharma (IPH) — Net Asset Quality Index
Innate Pharma (IPH) has a Net Asset Quality Index of -34.6% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €62.72 Million minus total liabilities of €84.42 Million yields net assets of €-21.70 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Innate Pharma to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Innate Pharma Net Asset Quality Index Over Time (2003–2025)
This chart shows how Innate Pharma's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the index stands at -34.6%, representing net assets of €-21.70 Million against total assets of €62.72 Million EUR. See Innate Pharma (IPH) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Innate Pharma (2003–2025)
The table below presents the year-by-year Net Asset Quality Index for Innate Pharma from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market cap of Innate Pharma.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -34.6% | €-21.70 Million | €62.72 Million | €84.42 Million | ▼ -42.6 pp |
| 2024 | 8.0% | €8.83 Million | €111.06 Million | €102.22 Million | ▼ -20.2 pp |
| 2023 | 28.2% | €51.90 Million | €184.19 Million | €132.29 Million | ▲ +2.1 pp |
| 2022 | 26.1% | €54.15 Million | €207.86 Million | €153.71 Million | ▼ -14.1 pp |
| 2021 | 40.2% | €107.44 Million | €267.50 Million | €160.06 Million | ▼ -10.6 pp |
| 2020 | 50.7% | €155.97 Million | €307.42 Million | €151.45 Million | ▼ -3.4 pp |
| 2019 | 54.2% | €217.42 Million | €401.36 Million | €183.94 Million | ▲ +17.1 pp |
| 2018 | 37.1% | €167.24 Million | €451.22 Million | €283.98 Million | ▲ +3.4 pp |
| 2017 | 33.7% | €85.96 Million | €255.02 Million | €169.07 Million | ▲ +3.1 pp |
| 2016 | 30.6% | €86.17 Million | €281.58 Million | €195.41 Million | ▲ +7.0 pp |
| 2015 | 23.6% | €72.07 Million | €305.96 Million | €233.89 Million | ▼ -58.7 pp |
| 2014 | 82.3% | €74.63 Million | €90.69 Million | €16.06 Million | ▲ +10.2 pp |
| 2013 | 72.1% | €40.29 Million | €55.88 Million | €15.60 Million | ▲ +23.7 pp |
| 2012 | 48.4% | €23.36 Million | €48.30 Million | €24.93 Million | ▲ +4.1 pp |
| 2011 | 44.3% | €26.62 Million | €60.11 Million | €33.48 Million | ▼ -25.5 pp |
| 2010 | 69.8% | €33.52 Million | €48.01 Million | €14.49 Million | ▼ -3.6 pp |
| 2009 | 73.4% | €47.12 Million | €64.22 Million | €17.10 Million | ▲ +5.5 pp |
| 2008 | 67.9% | €41.34 Million | €60.86 Million | €19.52 Million | ▼ -10.6 pp |
| 2007 | 78.5% | €49.61 Million | €63.15 Million | €13.55 Million | ▼ -2.8 pp |
| 2006 | 81.4% | €56.37 Million | €69.25 Million | €12.89 Million | ▲ +0.4 pp |
| 2005 | 81.0% | €20.07 Million | €24.77 Million | €4.70 Million | ▼ -3.7 pp |
| 2004 | 84.8% | €25.01 Million | €29.51 Million | €4.50 Million | ▲ +10.6 pp |
| 2003 | 74.1% | €15.11 Million | €20.38 Million | €5.27 Million | — |